713121-80-3
713121-80-3
Chemical Structure
ML-193
Synonym(s): CID 1261822
- CAS No.: 713121-80-3
- Formula:C28H25N5O4S
- Molecular Weight:527.59
IUPAC Name: N-(4-(N-(3,4-dimethylisoxazol-5-yl)sulfamoyl)phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide
InChIKey: HTSLEZOTMYUPLU-UHFFFAOYSA-N
SMILES: CC(C(C)=NO1)=C1NS(C(C=C2)=CC=C2NC(C3=CC(C4=CC=CC=N4)=NC5=C3C=C(C)C=C5C)=O)(=O)=O
Biological Activity: ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ML-193 | 99.68% | ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ML-193 (Standard) | ≥98% | ML-193 (Standard) is the analytical standard of ML-193 (HY-110125). This product is intended for research and analytical applications. ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of ParKinson’s disease (PD) rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Heynen-Genel S, et, al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program. 2010 Oct 30. [Content Brief]
- [2]. Kotsikorou E, et, al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2013 Dec 31;52(52):9456-69. [Content Brief]
- [3]. Fatemi I, et, al. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model. Acta Neuropsychiatr. 2021 Feb;33(1):15-21. [Content Brief]
